EE200100649A - A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks - Google Patents

A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks

Info

Publication number: EE200100649A
Authority: EE; Estonia
Prior art keywords: preparation; methods; beta peptide; peptide compositions; compositions
Prior art date: 1999-06-01

Application number

EEP200100649A

Other languages

English (en)

Estonian (et)

Inventor

Hirtzer Pamela

Patel Naina

Original Assignee

Neuralab Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-01

Filing date

2000-06-01

Publication date

2003-02-17

2000-06-01 Application filed by Neuralab Limited filed Critical Neuralab Limited

2003-02-17 Publication of EE200100649A publication Critical patent/EE200100649A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Mycology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Marine Sciences & Fisheries (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EEP200100649A 1999-06-01 2000-06-01 A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks EE200100649A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13704799P	1999-06-01	1999-06-01
PCT/US2000/015302 WO2000072870A1 (en)	1999-06-01	2000-06-01	Compositions of a-beta peptide and processes for producing same

Publications (1)

Publication Number	Publication Date
EE200100649A true EE200100649A (et)	2003-02-17

Family

ID=22475602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100649A EE200100649A (et)	1999-06-01	2000-06-01	A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks

Country Status (25)

Country	Link
EP (1)	EP1181040A1 (is)
JP (1)	JP2003519620A (is)
KR (1)	KR20020016813A (is)
CN (1)	CN1353615A (is)
AR (1)	AR024558A1 (is)
AU (1)	AU5726100A (is)
BG (1)	BG106249A (is)
BR (1)	BR0011251A (is)
CA (1)	CA2374897A1 (is)
CZ (1)	CZ20014150A3 (is)
EE (1)	EE200100649A (is)
HK (1)	HK1045938A1 (is)
HR (1)	HRP20010901A2 (is)
IL (1)	IL146575A0 (is)
IS (1)	IS6182A (is)
MX (1)	MXPA01012355A (is)
NO (1)	NO20015859L (is)
NZ (1)	NZ515744A (is)
PE (1)	PE20010212A1 (is)
PL (1)	PL352575A1 (is)
RU (1)	RU2001135800A (is)
SK (1)	SK17012001A3 (is)
TR (1)	TR200103476T2 (is)
WO (1)	WO2000072870A1 (is)
ZA (1)	ZA200109704B (is)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
EP1309341A2 (en)	2000-07-07	2003-05-14	Lars Lannfelt	Prevention and treatment of alzheimer's disease
WO2002025279A2 (en) *	2000-09-19	2002-03-28	Evotec Neurosciences Gmbh	Use of amyloid precursor protein for treating brain amyloidosis
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
MY144532A (en)	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
CA2590337C (en)	2004-12-15	2017-07-11	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
US7625560B2 (en)	2004-12-15	2009-12-01	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
DK1954718T3 (en)	2005-11-30	2014-12-15	Abbvie Inc	Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
CN101506236B (zh)	2005-11-30	2012-12-12	雅培制药有限公司	抗淀粉样β蛋白的单克隆抗体及其用途
DE602007011415D1 (de)	2006-03-23	2011-02-03	Bioartic Neuroscience Ab	Verbesserte protofibrilselektive antikörper und deren verwendung
WO2009017467A1 (en)	2007-07-27	2009-02-05	Elan Pharma International Limited	Treatment of amyloidogenic diseases
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en)	2007-02-27	2010-12-09	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
MX360403B (es)	2010-04-15	2018-10-31	Abbvie Inc	Proteinas de union a amiloide beta.
JP6147665B2 (ja)	2010-08-14	2017-06-14	アッヴィ・インコーポレイテッド	アミロイドベータ結合タンパク質
GB201113570D0 (en)	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
AU2015286707B2 (en)	2014-07-10	2020-05-21	Bioarctic Neuroscience Ab	Improved A beta protofibril binding antibodies
MY195190A (en)	2016-01-08	2023-01-11	Ascendis Pharma Growth Disorders As	Controlled-Release Cnp Agonists With Increased Nep Stability
EP3400019B1 (en)	2016-01-08	2022-09-28	Ascendis Pharma Growth Disorders A/S	Cnp prodrugs with carrier attachment at the ring moiety
IL318754A (en)	2016-01-08	2025-04-01	Ascendis Pharma Growth Disorders As	Controlled-release CNP agonists with low initial NPR-B activity
CN114957438B (zh) *	2022-06-28	2024-04-02	福建亿彤生物科技有限公司	用于检测阿尔茨海默病的人Aβ1-42抗原决定簇多肽及制法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0526511B1 (en) *	1990-04-27	1997-05-28	MCMICHAEL, John	Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

2000
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/es not_active Application Discontinuation
- 2000-05-31 AR ARP000102690A patent/AR024558A1/es unknown
- 2000-06-01 PL PL00352575A patent/PL352575A1/xx not_active Application Discontinuation
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/es unknown
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/ko not_active Withdrawn
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/sk unknown
- 2000-06-01 EE EEP200100649A patent/EE200100649A/xx unknown
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/pt not_active Application Discontinuation
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/ja not_active Withdrawn
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/ru unknown
- 2000-06-01 IL IL14657500A patent/IL146575A0/xx unknown
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Application Discontinuation
- 2000-06-01 HR HR20010901A patent/HRP20010901A2/hr not_active Application Discontinuation
- 2000-06-01 HK HK02106241.2A patent/HK1045938A1/zh unknown
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/cs unknown
- 2000-06-01 CN CN00808374A patent/CN1353615A/zh active Pending
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/xx unknown
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/is unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/no not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/xx unknown

Also Published As

Publication number	Publication date
MXPA01012355A (es)	2003-06-24
NO20015859D0 (no)	2001-11-30
AR024558A1 (es)	2002-10-16
WO2000072870A1 (en)	2000-12-07
IS6182A (is)	2001-11-29
BR0011251A (pt)	2002-03-05
ZA200109704B (en)	2003-02-26
AU5726100A (en)	2000-12-18
BG106249A (en)	2002-08-30
EP1181040A1 (en)	2002-02-27
CA2374897A1 (en)	2000-12-07
SK17012001A3 (sk)	2002-06-04
IL146575A0 (en)	2002-07-25
HK1045938A1 (zh)	2002-12-20
JP2003519620A (ja)	2003-06-24
NO20015859L (no)	2002-02-01
CN1353615A (zh)	2002-06-12
HRP20010901A2 (en)	2003-04-30
RU2001135800A (ru)	2003-08-20
KR20020016813A (ko)	2002-03-06
NZ515744A (en)	2004-04-30
CZ20014150A3 (cs)	2002-05-15
PE20010212A1 (es)	2001-02-22
PL352575A1 (en)	2003-08-25
TR200103476T2 (tr)	2002-04-22

Publication	Publication Date	Title
EE200100649A (et)	2003-02-17	A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks
IS5046A (is)	1999-11-16	Lyfjasamsetningar
ID27415A (id)	2001-04-05	Komposisi farmaseutik
NO20015175L (no)	2001-10-23	Farmasöytisk sammensetning
PT1165069E (pt)	2005-01-31	Composicao sinergistica antitumoral
FI991485L (fi)	2000-12-31	Uusi farmaseuttinen koostumus
DE69933200D1 (de)	2006-10-26	Kombinierte impfstoffzusammensetzungen
NO20004758L (no)	2000-11-08	Vaksinesammensetning
PT1242087E (pt)	2004-06-30	Composicoes farmaceuticas
DK0911385T3 (da)	2004-02-02	Stanolholdige sammensætninger
ID29262A (id)	2001-08-16	Komposisi farmasi
FI991302A7 (fi)	1999-06-08	Parannetut farmaseuttiset koostumukset
ID27201A (id)	2001-03-08	Komposisi farmasi
DE69943245D1 (de)	2011-04-14	Gaserzeugende zusammensetzung
PT1239832E (pt)	2004-10-29	Composicoes farmaceuticas
IS2515B (is)	2009-06-15	Lyfjasamsetningar
FI4488U1 (fi)	2000-07-20	Farmaseuttinen koostumus
DE60020682D1 (de)	2005-07-14	Resorcinenthaltende zusammensetzung
EE200000459A (et)	2002-02-15	Farmatseutilised kompositsioonid
ID27329A (id)	2001-03-29	Komposisi penghambat
DE60005188D1 (de)	2003-10-16	Grf-haltige lyophilisierte arzneizusammensetzungen
NO994436D0 (no)	1999-09-13	Farmasöytiske sammensetninger
SE9902685D0 (sv)	1999-07-13	Stable protein compositions
SE9800052D0 (sv)	1998-01-13	Pharmaceutical compositions
FI981567A0 (fi)	1998-07-07	Farmaseuttiset koostumukset